IL6ST

Across TCGA pan-cancer cohorts, IL6ST Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IL6ST data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher IL6ST Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IL6ST expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

READ, ESCA, and UCEC are the cancer types where IL6ST Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.082	0.820	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.136	0.703	<.001	21	view →
UCEC	DFS	Median	II,III,IV	0.915	0.437	.030	10	view →
SKCM	DFS	Median	III,IV	0.015	0.648	<.001	5	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IL6ST–READ (DFS)

Open the READ breakdown →